SEC Form 4 · accession 0001337252-26-000003
Cytek Biosciences, Inc. · CTKB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Chin
Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 12, 2026 · 7:27 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001831915
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jun 10, 2026 | A | 33,333 | A | — | — | Common Stock | 33,333 | 33,333 | D |
| Director Stock Option (right to buy)F3 | $4.05 | Jun 10, 2026 | A | 18,261 | A | — | Jun 10, 2036 | Common Stock | 18,261 | 18,261 | D |
Explanation of responses
- F1Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).
- F3100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).